Àå¹Ù±¸´Ï ´Ù¿î·Îµå °í°´¼¾ÅÍ ÃæÀüÇϱâ ÀÚ·á¿äû È«º¸Çϱâ
 
·¹Æ÷Æ®¸¶ÄÏ ·Î°í
³×À̹ö
 
·¹Æ÷Æ® ÀÏ¹Ý³í¹® Ç¥Áö/¼­½Ä ¹æ¼ÛÅë½Å´ë ÀÚ·áµî·Ï
°Ë»ö¹öÆ°
 IDÀúÀå  º¸¾ÈÁ¢¼Ó
ID/ºñ¹Ð¹øÈ£ ã±â
ȸ¿ø°¡ÀÔ
¸¶Àϸ®Áö ÃæÀüÇϱâ
ÄÁÅÙÃ÷ Ä«Å×°í¸®
·¹Æ÷Æ®
ÀÏ¹Ý³í¹®
¹æ¼ÛÅë½Å´ë
Ç¥Áö/¼­½Ä
¿µ¾î·¹Æ÷Æ®
Ãë¾÷ÀÚ·á
Çѱۿöµå
ÈƹÎÁ¤À½ ¿öµåÆÄ¿öÆ÷ÀÎÆ®
¿¢¼¿¾ÆÅ©·Îºª
MS¿ÀÇǽº ȣȯÆÑ
°Ë»ö°á°ú
HOME °Ë»ö°á°ú
 
°Ë»ö°á°ú¾È³»
°Ë»ö°á°ú¾È³»
 °Ë»öÇϽŠ"SINGIN IN THE RAIN"ÀÇ °Ë»ö°á°ú 289°ÇÀÇ ÀÚ·á°¡ °Ë»öµÇ¾ú½À´Ï´Ù.
 Ãß°¡ ´Ü¾î ÀÔ·Â ÈÄ, °á°ú³» Àç°Ë»öÀ» ´©¸£½Ã¸é º¸´Ù Á¤È®ÇÑ °Ë»öÀÌ °¡´ÉÇÕ´Ï´Ù.
  °á°ú³» Àç°Ë»ö 
 
°Ë»ö°á°ú ÃÑ 289°³ÀÇ ÀÚ·á°¡ ÀÖ½À´Ï´Ù.
¹Ì¸®º¸±â
°æ¿µÄÁ¼³ÆÃÀÇ ¸ñÀû°ú Ư¡ ¹× ¸ÆŲÁö ±â¾÷ºÐ¼® (500¿ø, 43 Page)
°æ¿µÄÁ¼³Æÿ¡ ´ëÇÑ Á¾ÇÕÀûÀÎ Á¤ÀÇ ÄÁ¼³ÆÃÀÇ Æ¯Â¡ ÄÁ¼³ÆÃÀÇ ¸ñÀû ±â ¾÷ ¼Ò °³ ¼º Àå °ú Á¤ Àç µµ ¾à Á¶Á÷ü°è ¹× Àλç°ü¸® ¸ÆŲÁöÀÇ ¹Ì·¡
µî·ÏÀÏ: 2010.04.12 | µî·ÏÀÚ: nirvana9876
¹Ì¸®º¸±â
´õÆäÀ̽º¼¥(THE FACE SHOP) ¸¶ÄÉÆÃÀü·«°ú ¸¶ÄÉÆüº°ø»ç·Ê (500¿ø, 34 Page)
1. ÁÖÁ¦¼±Á¤ÀÌÀ¯ 2. ÆäÀ̽º ¼¥Àº? ºê·£µå ÄÁ¼Á 3. ȯ°æºÐ¼® °Å½Ãȯ°æ ºÐ¼® ¹Ì½Ãȯ°æ ºÐ¼® °í°´ºÐ¼® °æÀïÀÚ ºÐ¼® 4. SWOT ºÐ¼® °­Á¡ / ¾àÁ¡ / ±âȸ / À§Çù 4. 4PºÐ¼® Á¦Ç° (Product) °¡°Ý (Price) À¯Åë (Place) ÃËÁø (Promotion) 5. STP Àü·« Segmentation Targeting Positioning 6. ÇâÈÄ Àü..
µî·ÏÀÏ: 2010.04.11 | µî·ÏÀÚ: nirvana9876
¹Ì¸®º¸±â
HBR»ç·ÊºÐ¼® - ¸µÄÁÀÏ·ºÆ®¸¯(Lincoln Electrics)»ç·Ê (500¿ø, 13 Page)
1. ȸ»ç ¼Ò°³ 2. ÇØ¿Ü ÁøÃâ ¹è°æ 3. ÇØ¿Ü ÁøÃâ ÁøÇà °úÁ¤ 4. ÇØ¿Ü ÁøÃâ ÁøÇà °á°ú 5. ±Øº¹ °úÁ¤ 6. ½ÇÆÐ ¿øÀÎ 7. Discussion
µî·ÏÀÏ: 2010.04.07 | µî·ÏÀÚ: nirvana9876
¹Ì¸®º¸±â
B2B ÀüÀÚ»ó°Å·¡ »ç·ÊºÐ¼®-COVISINT, ÀÌ»ó³×Æ®¿÷½º (500¿ø, 29 Page)
°³°ü B2B¶õ?, ÃÖ±Ù µ¿Çâ 1À§ ±â¾÷ -ÇØ¿Ü: COVISINT, ±¹³»: ÀÌ»ó³×Æ®¿÷½º ½ÃÀå±Ô¸ð¿Í °æÀï»óȲ ¿¬Çõ SWOTºÐ¼®, BMºÐ¼®, À繫¼º°ú ÇâÈÄ Àü¸Á °á·Ð ÁÖ¿ä³»¿ë ¿ä¾à ¹× ½Ã»çÁ¡
µî·ÏÀÏ: 2010.04.05 | µî·ÏÀÚ: nirvana9876
¹Ì¸®º¸±â
ÀڱðæºÎ »óÇdz» Á¾¾ç(Cervical Intraepithelial Neoplasia, CIN) (1,500¿ø, 9 Page)
¥°. Áúº´°íÂû 1. ¹ß»ýºóµµ 2. º´¸® 1) Á¤ÀÇ 2) °¨º°Áø´Ü 3. ¿øÀÎ 1) À§Ç豺 2) °¨¿°¿äÀÎ : HPV(Human Papilloma Virus) 4. Áõ»ó 5. Áø´Ü 1) ¼¼Æ÷Áø °Ë»ç(PAP smear, Papanicolaou smear) 2) ÁúÈ®´ë°æ(Colposcopy) 3) HPV À¯Çü°Ë»ç(HPV typing) 4) ÀڱðæºÎ È®´ë ÃÔ¿µ¼ú(cervicogrphy) 5) ¿øÃß»ý°Ë(Coniza..
µî·ÏÀÏ: 2010.03.28 | µî·ÏÀÚ: rlarudtns
¹Ì¸®º¸±â
¾à¸®ÇÐ ½ÇÇè- Determination of LD50 (1,500¿ø, 7 Page)
󰊱 ½ÇÇè °á°ú (1) ¿ì¸®°¡ ½ÇÇèÇÑ Data ¨ç Litchfield-Wilcoxon ¹æ¹ý ¨è Behrens-Karber ¹æ¹ý (2) Á¶±³ ¼±»ý´Ô²²¼­ ÁֽŠData ¨ç Litchfield-Wilcoxon ¹æ¹ý ¨è Behrens-Karber ¹æ¹ý 󰊲 °á°ú ºÐ¼® ¹× Åä·Ð 󰊳 Assignment ¨ç Toxcity testÀÇ Á¾·ù ¨è StrychnineÀÇ µ¶¼º°ú ÀÛ¿ë±âÀü ¨é LD5..
µî·ÏÀÏ: 2010.03.28 | µî·ÏÀÚ: idjyh
Å°¿öµå: LD50DeterminationToxcityStrychnineµ¶¼º
¹Ì¸®º¸±â
¾à¸®ÇÐ ·¹Æ÷Æ®- Determination of LD50 (1,400¿ø, 7 Page)
* Determination of LD50 * Assignment 2. StrychnineÀÇ µ¶¼º°ú ÀÛ¿ë±âÀü 3. LD50 valueÀÇ ÀÓ»óÀ¸·Î Àû¿ë½Ã ¹®Á¦Á¡
µî·ÏÀÏ: 2010.03.28 | µî·ÏÀÚ: idjyh
¹Ì¸®º¸±â
¹«µî°æ±âÀå Ticketing ´ë±âÇà·ÄÀÇ ¹®Á¦Á¡°ú °³¼±¹æ¾È (2,000¿ø, 12 Page)
1.1 – ¼­·Ð 2.1 – ÇöÀç ´ë±âÇà·ÄÀÇ ¹®Á¦Á¡ 2.2 – ½ÇÁ¦ Data ¼öÁý 2.3 – ¿ì¼ö Ÿ±¸Àå Data ¼öÁý 2.4 – Simulation Modeling 2.5 – ¿¹»ó °³¼±¹æ¾È 2.6 – Modeling ºñ±³ ºÐ¼® 3.1 – °á·Ð
µî·ÏÀÏ: 2010.03.27 | µî·ÏÀÚ: idjyh
¹Ì¸®º¸±â
±¤ÁÖ ¹«µî°æ±âÀå Ticketing ´ë±âÇà·ÄÀÇ ¹®Á¦Á¡°ú °³¼±¹æ¾È (500¿ø, 2 Page)
1. Çö »óȲ 2. ´ë±âÇà·ÄÀ̶õ? 3. ÇöÀç ¹®Á¦Á¡ 4. °³¼±¹æ¾È 5. °á·Ð
µî·ÏÀÏ: 2010.03.27 | µî·ÏÀÚ: idjyh
¹Ì¸®º¸±â
·çµåºñÈ÷ ºñÆ®°Õ½´Å¸ÀÎ(Ludwig Josef Johann Wittgenstein) (500¿ø, 1 Page)
¾øÀ½
µî·ÏÀÏ: 2010.03.25 | µî·ÏÀÚ: idjyh
11 12 13 14 15 16 17 18 19 20
 
 
 
 
   
 
ȸ»ç¼Ò°³ °³ÀÎÁ¤º¸Ãë±Þ¹æħ ÀÌ¿ë¾à°ü °í°´¼¾ÅÍ À̸ÞÀϼöÁý°ÅºÎ Ã¥ÀÓÀÇ ÇÑ°è¿Í ¹ýÀû°íÁö ±¤°íÁ¦ÈÞ¹®ÀÇ
 
¡¤ ÁÖ¼Ò: °æ±âµµ °í¾ç½Ã ´ö¾ç±¸ Àººû·Î39(¼¼Àººôµù) | ÀüÈ­¹øÈ£: 070) 7738-7494
¡¤ »ç¾÷ÀÚµî·Ï¹øÈ£: 106-10-42118 | »ç¾÷ÀÚÁ¤º¸È®ÀÎ | ´ëÇ¥: ±èÇü¼ø
¡¤ Åë½ÅÆǸŹøÈ£: °í¾ç´ö¾ç±¸-0328È£ | °³ÀÎÁ¤º¸Ã¥ÀÓÀÚ: ±èÀ¯¶ó
¡¤ Copyright ¨Ï ÇÏ¿ìµô Ä¿¹Â´ÏÄÉÀÌ¼Ç All Rights Reserved. | °í°´¼¾ÅÍ ¹®ÀÇ À̸ÞÀÏ: help@reportmarket.co.kr
³×À̹ö ºí·Î±×  ÀνºÅ¸±×·¥  ÆäÀ̽ººÏ Æ®À§ÅÍ